The Pros and Cons of Corporate VCs
This article was originally published in Start Up
Executive Summary
There are both advantages and disadvantages for financial VCs considering a co-investment by a corporate venture investor. The pros include, the ability to draw on the extensive due diligence resources of the corporate parent company; benefiting from the corporate VC's skills at evaluating later stage risk; and the corporate VC's perspective of the customer. On the downside, the unpredictability of corporate VCs' ability to make follow-on investments; different expectations on returns; and potential conflicts-of-interest. In general, though corporate VC investment is a very good thing, and any associated negatives can be handled through the structuring of the relationship and by making sure that there are consistent expectations on both sides.
You may also be interested in...
Corporate VC Adds a Business Development Flavor
Nearly all the meters on pharma's pipeline are reading critical. With licensing and M&A increasingly a series of high-priced auctions, Big Pharma is casting about, often desperately, for new business-development strategies. And one place they're beginning to look is corporate venture capital, traditionally a way to provide drug companies with a window on new technologies. But that means finding a way to break through the seemingly impenetrable wall between corporate venture investing and other corporate and research activities. Thus, companies have embarked on a number of different strategies, ranging from the traditional to the radically new and aggressive. Getting the equity investor and the asset-hungry pharma partner to co-exist peacefully has aroused plenty of both skepticism and confusion Nevertheless, there's still a promising way for drug companies to get value from start-ups beyond mere equity appreciation--investing de-prioritized drug candidates, not merely capital.
Why Clinical Trials Fail Unexpectedly
Is there an explanation for the recent spate of biotech Phase II and Phase III clinical trial failures? It's almost impossible to give general reasons for specific clinical failures. Several hypotheses, borrowed from the tenets of behavioral finance, however, may help explain some recent, unanticipated later-stage setbacks. They may also support other studies that suggest that small biotech companies fail more often in clinical development than their larger biotech and pharma brethren.
Why Investors Adopt Orphans
Venture-backed biotech companies are increasingly seeking to commercialize drugs that qualify for orphan drug protection from the FDA; is this business model a good idea?